Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:22:36.531Z.
Calculation as of: 2026-10-06T18:22:36.531Z.
Quote observation: 2026-10-06T18:18:51.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 93909054c420831b7a71ade485d1565ba09f3c5b60377b98c71c30749e6fc511
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
PRF Technologies Ltd.
Market Cap
$71110.00
Price/FCF Ratio
N/A
Market Cap
$30509.00
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| PRF Technologies Ltd. (PRFX) | $71110.00 | N/A |
| Akanda Corp. (AKAN)vs › | $61495.00 | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $97282.00 | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $108729.00 | N/A |
| Zhongchao Inc. (ZCMD)vs › | $31083.00 | N/A |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $30509.00 | N/A |
| NewGenIvf Group Limited (NIVF)vs › | $6115.00 | N/A |
| SciSparc Ltd. (SPRC)vs › | $242924.00 | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $380715.00 | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
